Comparing and ranking antidepressants by clinical effects: Medications such as sertraline and escitalopram (SSRIs) are commonly first-line due to their efficacy in depression and anxiety with generally fewer drug interactions, but have notable sexual side effects including reduced libido and delayed ejaculation, as well as risks of emotional blunting and withdrawal symptoms. SNRIs like venlafaxine and desvenlafaxine have similar efficacy but higher overdose toxicity and may increase blood pressure. Mirtazapine is associated with sedation, improved sleep (thus beneficial for insomnia), weight gain, less sexual dysfunction, but can cause daytime drowsiness, with some preservation of motivation and cognition. Bupropion, not licensed in the UK but referenced in literature, generally has fewer sexual side effects and may improve motivation and alertness but carries seizure risk. Vortioxetine may improve cognition and motivation with a lower propensity for sexual side effects. Duloxetine and venlafaxine affect anxiety and depression but have varying side effect profiles, including risks for blood pressure elevation and withdrawal symptoms. Agomelatine acts differently (melatonin receptor agonist) with less sexual dysfunction but requires liver monitoring, and buspirone is an anxiolytic with less antidepressant efficacy alone but minimal sexual side effects. Vilazodone is not first-line in UK guidelines and data on side effects is less established. Withdrawal symptoms are more common with SSRIs and SNRIs compared to mirtazapine or agomelatine, and emotional blunting is most reported with SSRIs and SNRIs.
Suitability for a patient with predominant anxiety and adverse fluoxetine effects: Sertraline or escitalopram may be considered first owing to lower interaction risk than fluoxetine, and mirtazapine can be used especially if insomnia is prominent. Alternatives minimizing sexual dysfunction and emotional blunting with preserved cognition include vortioxetine and bupropion (where available). Agomelatine could be considered but with liver function monitoring. Venlafaxine and desvenlafaxine should be used cautiously due to risk of increased blood pressure and overdose toxicity.
Risks regarding seizure threshold, nocturnal phenomena, blood pressure, liver and kidney health: Bupropion lowers seizure threshold; venlafaxine can elevate blood pressure; agomelatine requires liver function monitoring; mirtazapine can cause sedation and weight gain impacting nocturnal phenomena; SSRIs generally have less impact on liver and kidney but QT prolongation is a concern especially with citalopram and escitalopram. Caution is advised in patients with hepatic or renal impairment irrespective of antidepressant choice.
Recommended medication combinations: Referral to specialist mental health services is advised before combination therapy. Options may include adding mirtazapine or trazodone to an SSRI to mitigate sexual dysfunction or augment antidepressant effect; second-generation antipsychotics may be used with caution given risks for motivation and emotional blunting. Electroconvulsive therapy, lamotrigine, or liothyronine augmentation are specialist options.
Top three options for discussion with psychiatrist: 1) Sertraline or escitalopram as lower-interaction SSRIs with close monitoring; 2) Mirtazapine for predominant anxiety with insomnia and fewer sexual side effects; 3) Vortioxetine for potential cognitive benefits and lower sexual dysfunction. These selections balance efficacy, side effect profiles, and patient history of SSRI intolerance, aiming to minimise sexual dysfunction, emotional blunting, and preserve cognition and motivation.
This approach emphasises individualised shared decision-making, regular monitoring, and specialist input for complex cases or when exploring combination therapies and novel agents NICE CG91,NICE NG222,NICE CKS.